(TRDA) Entrada Therapeutics - Overview
Stock: Oligonucleotide, Protein, RNA, Neuromuscular, Ocular
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.7% |
| Relative Tail Risk | -1.40% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -41.43 |
| Character TTM | |
|---|---|
| Beta | 1.135 |
| Beta Downside | 1.196 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.75% |
| CAGR/Max DD | -0.17 |
Description: TRDA Entrada Therapeutics December 31, 2025
Entrada Therapeutics (NASDAQ:TRDA) is a clinical-stage biotech that focuses on delivering RNA- and protein-based drugs to intracellular targets previously deemed “undruggable” using its proprietary Endosomal Escape Vehicle (EEV) platform. The company’s modular approach is intended to improve therapeutic index across multiple organ systems, with its current pipeline emphasizing neuromuscular (e.g., Duchenne muscular dystrophy) and ocular indications.
Key operational metrics (as of the most recent 10-Q filing, Q2 2024) show a cash balance of roughly **$68 million**, giving the firm an estimated **12-month runway** at its current burn rate of $5-6 million per quarter. R&D expense has risen to **~$22 million YoY**, reflecting accelerated pre-clinical work on three EEV-enabled candidates.
Sector-wide, the RNA-therapeutics market is projected to grow at a **CAGR of 12-15 % through 2030**, driven by expanding payer acceptance and the success of mRNA vaccines. Entrada’s ability to target intracellular pathways could position it to capture a share of this expanding market, but success hinges on demonstrating clinical efficacy and safety in early-stage trials-a high-risk, high-reward dynamic typical for early-stage biotech.
Given the limited public data and the early-stage nature of its pipeline, investors should treat Entrada as a speculative play; a material setback in any pre-clinical program would materially impair the company’s valuation assumptions.
For a deeper quantitative look at Entrada’s valuation metrics, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -103.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA -28.29 > 1.0 |
| NWC/Revenue: 510.8% < 20% (prev 183.4%; Δ 327.4% < -1%) |
| CFO/TA -0.31 > 3% & CFO -127.9m > Net Income -103.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.5m) vs 12m ago 2.05% < -2% |
| Gross Margin: 34.24% > 18% (prev 0.98%; Δ 3326 % > 0.5%) |
| Asset Turnover: 12.72% > 50% (prev 38.81%; Δ -26.09% > 0%) |
| Interest Coverage Ratio: -8.74 > 6 (EBITDA TTM -113.8m / Interest Expense TTM -13.5m) |
Altman Z'' -1.89
| A: 0.76 (Total Current Assets 338.3m - Total Current Liabilities 24.0m) / Total Assets 412.9m |
| B: -0.57 (Retained Earnings -233.9m / Total Assets 412.9m) |
| C: -0.24 (EBIT TTM -118.0m / Avg Total Assets 483.7m) |
| D: -3.23 (Book Value of Equity -233.3m / Total Liabilities 72.2m) |
| Altman-Z'' Score: -1.89 = D |
Beneish M 1.00
| DSRI: 4.30 (Receivables 3.20m/2.60m, Revenue 61.5m/215.2m) |
| GMI: 2.87 (GM 34.24% / 98.39%) |
| AQI: 1.18 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.29 (Revenue 61.5m / 215.2m) |
| TATA: 0.06 (NI -103.5m - CFO -127.9m) / TA 412.9m) |
| Beneish M-Score: 1.04 (Cap -4..+1) = D |
What is the price of TRDA shares?
Over the past week, the price has changed by -7.34%, over one month by +5.16%, over three months by +52.52% and over the past year by -21.36%.
Is TRDA a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TRDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | 69.8% |
| Analysts Target Price | 18 | 69.8% |
| ValueRay Target Price | 11.5 | 8.6% |
TRDA Fundamental Data Overview February 03, 2026
P/S = 7.1071
P/B = 1.3079
Revenue TTM = 61.5m USD
EBIT TTM = -118.0m USD
EBITDA TTM = -113.8m USD
Long Term Debt = 52.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.35m USD (from shortTermDebt, last quarter)
Debt = 52.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -40.9m USD (from netDebt column, last quarter)
Enterprise Value = 162.8m USD (437.2m + Debt 52.4m - CCE 326.8m)
Interest Coverage Ratio = -8.74 (Ebit TTM -118.0m / Interest Expense TTM -13.5m)
EV/FCF = -1.25x (Enterprise Value 162.8m / FCF TTM -129.8m)
FCF Yield = -79.73% (FCF TTM -129.8m / Enterprise Value 162.8m)
FCF Margin = -211.0% (FCF TTM -129.8m / Revenue TTM 61.5m)
Net Margin = -168.2% (Net Income TTM -103.5m / Revenue TTM 61.5m)
Gross Margin = 34.24% ((Revenue TTM 61.5m - Cost of Revenue TTM 40.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev 43.59%)
Tobins Q-Ratio = 0.39 (Enterprise Value 162.8m / Total Assets 412.9m)
Interest Expense / Debt = 8.48% (Interest Expense 4.45m / Debt 52.4m)
Taxrate = 1.29% (859.0k / 66.5m)
NOPAT = -116.5m (EBIT -118.0m * (1 - 1.29%)) [loss with tax shield]
Current Ratio = 14.08 (Total Current Assets 338.3m / Total Current Liabilities 24.0m)
Debt / Equity = 0.15 (Debt 52.4m / totalStockholderEquity, last quarter 340.7m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -40.9m / EBITDA -113.8m)
Debt / FCF = 0.31 (negative FCF - burning cash) (Net Debt -40.9m / FCF TTM -129.8m)
Total Stockholder Equity = 391.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.39% (Net Income -103.5m / Total Assets 412.9m)
RoE = -26.42% (Net Income TTM -103.5m / Total Stockholder Equity 391.5m)
RoCE = -26.58% (EBIT -118.0m / Capital Employed (Equity 391.5m + L.T.Debt 52.4m))
RoIC = -29.74% (negative operating profit) (NOPAT -116.5m / Invested Capital 391.5m)
WACC = 9.92% (E(437.2m)/V(489.6m) * Re(10.10%) + D(52.4m)/V(489.6m) * Rd(8.48%) * (1-Tc(0.01)))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 11.47%
Fair Price DCF = unknown (Cash Flow -129.8m)
EPS Correlation: 18.34 | EPS CAGR: -26.89% | SUE: -0.09 | # QB: 0
Revenue Correlation: 51.97 | Revenue CAGR: 17.92% | SUE: -0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.00 | Chg30d=-0.040 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-4.10 | Chg30d=-0.099 | Revisions Net=+0 | Growth EPS=-13.8% | Growth Revenue=-19.3%